Cognitive deficit

DAVOS ALZHEIMER’S COLLABORATIVE ANNOUNCES STRATEGIC PARTNERSHIP WITH THE FINGERS BRAIN HEALTH INSTITUTE AND ITS WORLD-WIDE FINGERS GLOBAL SCIENTIFIC COORDINATING CENTER TO ADVANCE STUDIES ON DELAYING ALZHEIMER’S PROGRESSION

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Government budget balance, Alzheimer Research Forum, DAC, Karolinska Institute, Doctor of Philosophy, Center, Dementia, Partnership, Clinical trial, Cognitive deficit, Board, Research, GLOBE, Risk, Physician, Disease, RCT, Randomized controlled trial, Fisher Center for Alzheimer's Research Foundation, World Economic Forum, Ageing, Davos, Indian Computing Olympiad, Patient, Conditional sentence, Global, Caregiver, Medical device, Pharmaceutical industry, MD, Disability

The partnership between DAC, FBHI and its World-Wide FINGERS Global Scientific Coordinating Center, serves as an opportunity to educate and engage physicians and consumers on risk reduction measures.

Key Points: 
  • The partnership between DAC, FBHI and its World-Wide FINGERS Global Scientific Coordinating Center, serves as an opportunity to educate and engage physicians and consumers on risk reduction measures.
  • We are excited to join forces with FBHI and its World-Wide FINGERS Global Scientific Coordinating Center to advance prevention studies around the world, beginning in Kenya, where rates of Alzheimers are growing, said George Vradenburg, Founding Chairman ofthe Board, Davos Alzheimers Collaborative.
  • FBHI hosts and runs the World Wide FINGERS Global Coordination Center, a central resource for the World Wide FINGERS Network.
  • The Global Coordination Center supports the global scientific activities of the World Wide FINGERS Network, including network coordination, clinical trial optimization, and joint analysis of data.

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Retrieved on: 
Thursday, October 6, 2022
Quality of life, LinkedIn, Pharmacology, Guanylate cyclase, Müllerian agenesis, Mitochondrial disease, Nitric oxide, Degenerative disease, Fatigue, Therapy, Social isolation, Population, CGMP, Cognition, Muscle weakness, Patient, Neuropsychiatric Disease and Treatment, ADV, NO, Research, Twitter, Program, Cell, Corporation, Seizure, Inflammation, Partnership, Nasdaq, Food, Trial of the century, Company, Cognitive deficit, Food and Drug Administration, Pain, IP, Corporate development, Safety, SGC, CNS, Physiology, GLOBE, Alzheimer's disease, DNA, CYCN, FDA, Kidney, CIAS, Biomarker, Encephalopathy, Pharmaceutical industry, Medical imaging, MELAS, Schizophrenia, Akebia

CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its mitochondrial disease-focused corporate strategic plan. Propelled by the positive data from the recently completed CY6463 Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) clinical study, the Company believes it has a unique opportunity to deliver the first-ever approved medicine for patients suffering from rare mitochondrial diseases, a family of debilitating, progressive, and ultimately fatal genetic diseases.

Key Points: 
  • Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases
    CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its mitochondrial disease-focused corporate strategic plan.
  • Organization: The Companys workforce is being tailored to the mitochondrial disease-focused strategy, leading to a reduction of approximately 45%, to 16 full-time employees.
  • Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments for mitochondrial diseases, including MELAS.
  • For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter ( @Cyclerion ) and LinkedIn ( www.linkedin.com/company/cyclerion ).

Neurowyzr and Allium Healthcare Announce a first-of-its-kind Partnership for Brain Health for Active Agers

Retrieved on: 
Wednesday, September 28, 2022
Venus, Neuroscience, Software, Diet, Risk, Brain, Nursing, World, LinkedIn, Population, Organization, Allium, Long-term care, Partnership, Stroke, Mild cognitive impairment, Intermediate, Active ageing, Cognitive deficit, CEO, Respite care, MCI, Solution, Dementia, Ageing, GLOBE, Health care, AI, Digital Solutions, Medical imaging

SINGAPORE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Neurowyzr, the Singapore Deep Neuroscience and Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Allium Healthcare to jointly develop brain health programs to help Active Agers screen, monitor, prevent and improve brain health.

Key Points: 
  • SINGAPORE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Neurowyzr, the Singapore Deep Neuroscience and Brain Capital company with a vision to optimize population and corporate brain health and performance using neuroscience-based digital solutions, announces a partnership with Allium Healthcare to jointly develop brain health programs to help Active Agers screen, monitor, prevent and improve brain health.
  • Allium will be the first Intermediate and Long-Term care (ILTC) provider in Asia-Pacific to provide Active Ageing programs focused on the brain, using Neurowyzrs Digital Brain Function Screen and future brain health solutions.
  • Neurowyzr will also work with Allium to roll out future digital neuroscience solutions such as Digital Brain Health Diagnostics and Digital Therapy.
  • Bernie Poh, CEO, Allium Healthcare commented, Allium Healthcare works with leading and innovative teams to transform our vision for the finest of hospitality and healthcare into a reality.

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Retrieved on: 
Thursday, August 25, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Neurology, Mental Health, Other Science, Research, Science, Clinical Trials, Government budget balance, Security (finance), COVID-19, Human, Connective tissue disease, Safety, Post-traumatic stress disorder, Form 10-K, Central nervous system, Fibromyalgia, APTX, Brain, Disease, Primate, Lewy body, Memory, Even and odd functions, Lists of diseases, U.S. Securities and Exchange Commission, Inc., Patient, Cognitive deficit, Nasdaq, Attention, Twitter, Dementia, Annual report, Private Securities Litigation Reform Act, Neurodegeneration, CNS, Pharmaceutical industry, NMDA

The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in 99 patients with mild cognitive impairment or mild dementia associated with Parkinsons disease or dementia with Lewy bodies.

Key Points: 
  • The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in 99 patients with mild cognitive impairment or mild dementia associated with Parkinsons disease or dementia with Lewy bodies.
  • Cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies is characterized by a broad range of deficits related to attention, memory, and executive function.
  • Current treatment options for cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies are limited, with only one approved treatment for Parkinsons disease dementia and no treatments approved for dementia with Lewy bodies.
  • NYX-458 is a novel oral NMDA receptor positive allosteric modulator currently in clinical development for the treatment of cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies.

Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays

Retrieved on: 
Wednesday, August 24, 2022
People, Apolipoprotein E, PET, Diagnosis, Caregiver, Research, Alzheimer's disease, Awareness, Brain, Disease, Milken Institute, Blood, Health, Alzheimer's Disease International, Mass spectrometry, Cognitive deficit, ROU, Clinical trial, Eisai, Dementia, AD, Efficiency, Center for Epidemiologic Studies Depression Scale, Neurodegeneration, Government budget balance, Adoption, Patient, Medical imaging, Medical device, Residential care

(1) Accurate diagnosis remains a barrier to early and proper care management; research reviews estimate that between 40 and 60 percent of adults with probable dementia are undiagnosed.

Key Points: 
  • (1) Accurate diagnosis remains a barrier to early and proper care management; research reviews estimate that between 40 and 60 percent of adults with probable dementia are undiagnosed.
  • (2) Importantly, blood-based assays may be able to help identify which patients may benefit from therapy, and therefore may help streamline care and reduce healthcare spending.
  • C2N Diagnostics ("C2N") is a specialty diagnostics company with a vision to bring Clarity Through Innovation.
  • C2N strives to provide exceptional laboratory services and products in the field of brain health.

Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on: 
Friday, August 19, 2022
Electronic Games, Technology, Mental Health, Medical Devices, Neurology, Entertainment, Software, Health, Pharmaceutical, Slate, COVID-19, Decision-making, CEO, Technology, Research, SCS, Food and Drug Administration, Brain, Multiple sclerosis, Risk, Variable, Medicine, BofA Securities, Company, LLC, MDD, Founder, Patient, Conditional sentence, University of California, San Francisco, Credit Suisse, Nasdaq, Â, PureTech Health, Skadden, SEC, FDA, Communication, ADHD, MS, Lists of diseases, Industry, Government budget balance, Morgan Stanley, Hand, Social capital, PIPE, ASD, Wachtell, Lipton, Rosen & Katz, Cognitive deficit, Acquisition, Autism, University, Frustration, Attention deficit hyperactivity disorder predominantly inattentive, Psychiatry, Amnesia, UnitedHealth Group, Therapy, Forward-looking statement, Neuropsychiatric Disease and Treatment, Pharmaceutical industry, Risk management, Medical device, Neurology, Physiology, Yolo Akili

Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp.

Key Points: 
  • Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp.
  • The newly formed company, Akili, Inc. (Akili), is expected to start trading on The Nasdaq Capital Market (Nasdaq) under the new ticker symbol AKLI on August 22, 2022.
  • Eddie Martucci, CEO of Akili, said: Todays milestone reflects the combined efforts of the committed Akili team and SCS who together made this defining moment possible.
  • I look forward to working with Eddie and the Akili team as they enter this new and exciting chapter.

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022
Trial of the century, GLOBE, Mitochondrial encephalomyopathy, Harvard University, Board, Research, Patient, Pharmacology, AES, MIT, Board of directors, Development, MRI, Food, Nitric oxide, Disease, CSF, Government budget balance, CNS, Guanylate cyclase, PET, Șaeș, Safety, Pathology, Nasdaq, Alzheimer's disease, NO, Pharmacokinetics, ADV, NASA Distinguished Service Medal, EEG, Disorder, Broad Institute, Janssen Pharmaceuticals, CIAS, Therapy, Harald, Physiology, SGC, Food and Drug Administration, FDA, State Administrative Expenses, Biomarker, Cognitive deficit, Cognition, CGMP, UMDF, Company, Twitter, CYCN, LinkedIn, Administration, Pharmaceutical industry, Medical imaging, MELAS, Schizophrenia

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced second quarter 2022 financial results and a business update.

Key Points: 
  • Dr. Hecht continued: The promising clinical results we have seen to date strongly support the advancement of CY6463, a first-in-class, CNS-penetrant sGC stimulator.
  • Research & Development Expenses: R&D expenses were approximately $10.2 million for the second quarter of 2022, as compared to approximately $12.1 million for the second quarter of 2021.
  • General and Administrative Expenses: G&A expenses were approximately $3.5 million for the second quarter of 2022, as compared to approximately $6.2 million for the second quarter of 2021.
  • Net Loss: Net loss was approximately $13.4 million for the second quarter of 2022, as compared to $16.2 million for the second quarter of 2021.

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Retrieved on: 
Thursday, July 28, 2022
Food and Drug Administration, Cognitive deficit, ERP, Ageing, CNS, Safety, Disorder, Broad Institute, MELAS, CIAS, Company, LinkedIn, Șaeș, Quantitative electroencephalography, Population, Government budget balance, CYCN, Delusion, Alzheimer's disease, Neuropsychiatry, NO, Research, Biomarker, Nitric oxide, Stanley Center for Psychiatric Research at Broad Institute, ADV, AES, Guanylate cyclase, SGC, Cognition, GLOBE, Pharmacology, EEG, CGMP, Twitter, Food, Nasdaq, Mitochondrial encephalomyopathy, Therapy, Plasma, Trial of the century, Hallucination, Psychiatry, Movement, EDT, Inflammation, Drug development, Patient, Pharmacokinetics, Physiology, Dietary supplement, Pharmaceutical industry, Medical device, Online shopping, Schizophrenia

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS) in individuals with stable schizophrenia on a stable, single, atypical antipsychotic regimen. Data from the 14-day, double-blind, randomized, placebo-controlled, multiple-ascending-dose study demonstrate that once-daily CY6463 was safe and well tolerated, with no reports of serious adverse events (SAEs), severe adverse events (AEs), or treatment discontinuation due to AEs. Study data demonstrate a strong effect on cognitive performance after two weeks of 15mg once-daily dosing. A broad positive movement on inflammatory biomarkers was also observed. These signals on exploratory endpoints provide further evidence of the pro-cognitive and anti-inflammatory effects of CY6463 observed in preclinical studies and prior clinical trials.

Key Points: 
  • I am encouraged by the promising cognition signals observed after only two weeks of CY6463 dosing in patients with stable schizophrenia.
  • These data demonstrate the therapeutic potential of amplifying sGC signaling in the CNS, including positive effects on cognition and inflammation, and support further development of CY6463 in diseases characterized by cognitive impairment.
  • The clinical study enrolled 48 participants with stable schizophrenia with no more than moderate positive symptoms and on a stable, single, atypical antipsychotic regimen.
  • Cognitive impairment is a core, debilitating, and untreated symptom of schizophrenia, with nearly all patients suffering from some cognitive deficits.

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program Wi

Retrieved on: 
Wednesday, July 27, 2022
Patient, Celltrion, Cognitive deficit, Ageing, File, Social work, US, Safety, NIHR, Company, Security (finance), Hip, University, Population, Inflammation, Brain, Department of Health and Social Care, Life, MHRA, TNF, Research, Learning, Organic, Trauma, Compte rendu, Memory, PALO, Hippocampus, Program, Growth, List of life sciences, IND, Health care, GLOBE, Industry, Rheumatoid arthritis, CEO, SEC, Government, Health, Agency, Delirium, Secretary of State for International Development, Public health, Achievement, FDA, Nasdaq, Annual report, Risk, National Institute, Private Securities Litigation Reform Act, University of Oxford, NHS, NASDAQ, Behavior, Drug development, Investigational New Drug, Department, Pharmaceutical industry, Medical device, Dentistry, Health insurance, Medicine, Infliximab, Infliximab, EU

The trial is jointly funded by NIHR and 180 Life Sciences and is expected to be open for enrollment in the first half of 2023.

Key Points: 
  • The trial is jointly funded by NIHR and 180 Life Sciences and is expected to be open for enrollment in the first half of 2023.
  • This is a major achievement by the team, said Dr. Jim Woody, CEO of 180 Life Sciences.
  • As previously disclosed, an issued patent to protect this potential use has been licensed by 180 Life Sciences from The Kennedy Trust for Rheumatology Research.
  • 180 Life Sciences also has the rights for commercialization of the trial results.

The Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of Akili’s AKL-T01 Product Candidate

Retrieved on: 
Thursday, July 14, 2022
Software, Technology, General Health, Health, Technology, Lists of diseases, Prevalence, Government budget balance, MJ, University of Maryland Human–Computer Interaction Lab, Safety, Psychiatry, University of Colorado School of Medicine, JG, Communication, Pediatric acute-onset neuropsychiatric syndrome, SLE, Attention, ASD, Risk, Multiple sclerosis, National Jewish Health, Patient, Cognitive deficit, Ageing, Systematic review, Brain, COVID-19, Lupus, Cognitive disorder, Rheumatology, Autism spectrum, Monitor, Non-functional testing, Medicine, Degenerative disease, Discoid lupus erythematosus, WAIS-IV, SSME, Even and odd functions, Forward-looking statement, ADHD, MS, Research, Quality of life, University, Industry, Pharmaceutical industry, Medical device, Risk management, Neurology, Yolo Akili

Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.

Key Points: 
  • Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.
  • Further, the study investigated the ability of the product EVOTM Monitor5, built on the same technology platform, to serve as a rapid mobile assessment of cognitive function.
  • The results of this study in patients with SLE are consistent with the cognitive improvements seen in other studies after using our digital therapeutic.
  • Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: a systematic review.